Is there a moderate range of impact of financialization on corporate R&D?

被引:6
|
作者
Li, Zhenghui [1 ]
Wang, Yan [2 ]
机构
[1] Guangzhou Univ, Guangzhou Inst Int Finance, Guangzhou, Peoples R China
[2] Guangzhou Univ, Sch Econ & Stat, Guangzhou, Peoples R China
来源
PLOS ONE | 2021年 / 16卷 / 06期
关键词
FINANCING INNOVATION; INVESTMENT EVIDENCE; ECONOMIC-GROWTH; FIRMS; CASH; RESPONSIBILITY; SECTOR; REAL; FLOW;
D O I
10.1371/journal.pone.0253380
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
How to promote corporate research and development is a particularly important issue under the background of the economy being diverted out of the real economy. By selecting samples of 1221 Chinese A-share non-financial listed companies from 2010 to 2019, this paper examines the impact of financialization on research and development through the panel threshold regression model. Then, the moderate range of the impact of financialization on corporate research and development is measured, as well as their heterogeneity is also analyzed. The research shows the following results: first, there is a dynamic relationship and moderate range between financialization and corporate research and development. Financialization has a positive effect on corporate research and development when the level of financialization exceeds 0.4748. Secondly, from further heterogeneous research, financialization has a threshold effect on research and development among enterprises with a high level of research and development. In addition, there is a promoting effect on corporate research and development only when their financialization level exceeds 0.0097 in enterprises with a high level of research and development. Therefore, in order to promote corporate research and development, financialization of non-financial enterprises should make adjustment and regulation according to the action and direction of moderate range.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Research on the moderate range of enterprise financialization and R&D innovation from a nonlinear perspective
    Liu, Yue
    Huang, Shan
    Wang, Zirui
    Zhang, Lichang
    [J]. ELECTRONIC RESEARCH ARCHIVE, 2024, 32 (03): : 1923 - 1945
  • [2] Corporate governance and the impact to the R&D lab
    Markus, Arjan
    Swift, Tim
    [J]. JOURNAL OF STRATEGY AND MANAGEMENT, 2020, 13 (01) : 91 - 110
  • [3] THE IMPACT OF R&D EXPENDITURES ON CORPORATE PERFORMANCE: THE CASE OF WORLD R&D COMPANIES
    Ravselj, Dejan
    Aristovnik, Aleksander
    [J]. PROCEEDINGS OF FEB ZAGREB 10TH INTERNATIONAL ODYSSEY CONFERENCE ON ECONOMICS AND BUSINESS, 2019, 1 (01): : 658 - 667
  • [4] IMPACT OF CORPORATE R&D ON EFFICIENCY IN OECD INDUSTRIES
    Dos-Santos, Maria Jose Palma Lampreia
    Diz, Henrique
    [J]. INNOVATION, ENTREPRENEURSHIP AND DIGITAL ECOSYSTEMS, 2016, : 645 - 658
  • [5] Corporate decision-making in R&D outsourcing and the impact on internal R&D employment intensity
    Teirlinck, Peter
    Dumont, Michel
    Spithoven, Andre
    [J]. INDUSTRIAL AND CORPORATE CHANGE, 2010, 19 (06) : 1741 - 1768
  • [6] The Impact of R&D Expenditures on Corporate Performance: Evidence from Slovenian and World R&D Companies
    Ravselj, Dejan
    Aristovnik, Aleksander
    [J]. SUSTAINABILITY, 2020, 12 (05)
  • [7] Financialization and the Slowdown in Korean Firms' R&D Investment
    Seo, Hwan Joo
    Kim, Han Sung
    Kim, Yoo Chan
    [J]. ASIAN ECONOMIC PAPERS, 2012, 11 (03) : 35 - 49
  • [8] Pharmaceutical regulation in Europe and its impact on corporate R&D
    Eger, Stephan
    Mahlich, Joerg C.
    [J]. HEALTH ECONOMICS REVIEW, 2014, 4
  • [9] PHARMACEUTICAL REGULATION IN EUROPE AND ITS IMPACT ON CORPORATE R&D
    Mahlich, J.
    Eger, S.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A487 - A487
  • [10] Does director interlock impact corporate R&D investment?
    Han, Jie
    Bose, Indranil
    Hu, Nan
    Qi, Baolei
    Tian, Gaoliang
    [J]. DECISION SUPPORT SYSTEMS, 2015, 71 : 28 - 36